title: Formulation development of metoprolol succinate and hydrochlorothiazide compression coated tablets.
abstract: The purpose of present research work was to design and optimize compression coated tablet to provide an immediate release of hydrochlorothiazide in stomach and extended release of metoprolol succinate in intestine. Compression coated tablet was prepared by direct compression method which consisted of metoprolol succinate extended release core tablet and hydrochlorothiazide immediate release coat layer. Barrier coating of Hydroxy Propyl Methyl Cellulose (HPMC) E15LV was applied onto the core tablets to prevent burst release of metoprolol succinate in acidic medium. A 32 full factorial design was employed for optimization of the amount of polymers required to achieve extended release of drug. The percentage drug release at given time Q3, Q6, Q10, Q22; were selected as dependent variables. Core and compression coated tablets were evaluated for pharmaco-technical parameters. In vitro drug release of optimized batch was found to comply with Pharmacopoeial specifications. Desired release of metoprolol succinate was obtained by suitable combination of HPMC having high gelling capacity and polyethylene oxide having quick gelling capacity. The mechanism of release of metoprolol succinate from all batches was anomalous diffusion. Optimised batch was stable at accelerated conditions up to 3 months. Thus, compression coated tablet of metoprolol succinate and hydrochlorothiazide was successfully formulated.
authors.affiliation: Maliba Pharmacy College, Bardoli Mahuva Road, Tarsadi, Surat 394 350, India. ritesh_shah7@yahoo.com.
authors.forename: Ritesh
authors.initials: R
authors.lastname: Shah
authors.forename: Swatil
authors.initials: S
authors.lastname: Parmar
authors.forename: Hetal
authors.initials: H
authors.lastname: Patel
authors.forename: Sonia
authors.initials: S
authors.lastname: Pandey
authors.forename: Dinesh
authors.initials: D
authors.lastname: Shah
mesh_terms: D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000737:chemistry; D003692:Delayed-Action Preparations; D004058:Diffusion; D004339:Drug Compounding / Q000379:methods; D004355:Drug Stability; D004356:Drug Storage; D005079:Excipients / Q000737:chemistry*; D006852:Hydrochlorothiazide / Q000008:administration & dosage* / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D065347:Hypromellose Derivatives; D008747:Methylcellulose / Q000031:analogs & derivatives / Q000737:chemistry; D008790:Metoprolol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D010602:Pharmacopoeias as Topic; D011092:Polyethylene Glycols / Q000737:chemistry; D011108:Polymers / Q000737:chemistry; D013607:Tablets
chemical_list: D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D005079:Excipients; D011108:Polymers; D013607:Tablets; D006852:Hydrochlorothiazide; D065347:Hypromellose Derivatives; D011092:Polyethylene Glycols; D008747:Methylcellulose; D008790:Metoprolol